Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru DEC 2009
    - OnBioVC 2009 Year-in-Review, now available
    - OnBioVC 1Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • business strategy life science

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers.

*Estimated first close of round

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Zosano Pharma (Fremont, CA) a clinical-stage device company focused on a transdermal microprojection delivery system for needle-free administration therapeutic peptides, small molecules and vaccines. Participants include Nomura Phase4 Ventures, New Enterprise Associates, HBM BioVentures and ProQuest Investments.

Parasol Therapeutics (Cambridge, MA) a seed-stage company focused on treatments and diagnostics for influenza, closed a $3.3M Series A financing. Participants include Polaris Venture Partners, Flagship Ventures and Lux Capital.

HX Diagnostics (Emeryville, CA) an early-stage diagnostics company developing seasonal and pandemic influenza assays, closed a $3.1M Series A financing. Participants include Kleiner Perkins Caufield & Byers, Nanogen and Xiamen YST Biotech.

  

to top of page...